According to the Board, Duo-Cotexcin is only under quarantine pending investigations after failing a quality test/FILE
NAIROBI, Kenya, Mar 23 – The Pharmacy and Poisons Board has refuted claims that it re called an anti-malaria drug from the Kenyan market.
According to the Board, Duo-Cotexcin is only under quarantine pending investigations after failing a quality test.
It explained that it is undertaking investigations to ascertain the suspected quality defect on a specific batch.
“No recall or withdrawal is being conducted for the above product. The Pharmacy and Poisons Board is undertaking investigations to ascertain the suspected quality defect on that specific batch No 160621.”
The Board assured all stakeholders that they shall be informed on the outcome of investigations once concluded.
About The Author
